Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion | TA283 | | |
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration | TA155 | | |
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia | TA298 | | |
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver | IPG786 | | |
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes | IPG787 | | |
Image-guided percutaneous laser ablation for primary and secondary liver tumours | IPG788 | | |
Atogepant for preventing migraine | TA973 | | |
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma | TA974 | | |
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under | TA975 | | |
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments | TA970 | | |
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | TA971 | | |
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over | TA967 | | |
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | TA540 | | |
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) | TA969 | | |
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA968 | | |
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) | TA966 | | |
Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema | IPG785 | | |
Endometriosis: diagnosis and management | NG73 | | |
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma | TA964 | | |
Twin and triplet pregnancy | NG137 | | |
Kurin Lock for blood culture collection | MTG77 | | |
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA963 | | |
GaitSmart rehabilitation exercise programme for gait and mobility issues | MTG78 | | |
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer | IPG784 | | |
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) | TA961 | | |
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA962 | | |
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) | TA965 | | |
Ritlecitinib for treating severe alopecia areata in people 12 years and over | TA958 | | |
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis | TA959 | | |
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) | TA960 | | |
Ovarian cancer: identifying and managing familial and genetic risk | NG241 | | |
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms | TA957 | | |
Suspected sepsis: recognition, diagnosis and early management | NG51 | | |
Neonatal infection: antibiotics for prevention and treatment | NG195 | | |
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management | NG240 | | |
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | TA878 | | |
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema | TA953 | | |
Dupilumab for treating moderate to severe prurigo nodularis | TA955 | | |
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over | TA956 | | |
Lung cancer: diagnosis and management | NG122 | | |
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA954 | | |
Vitamin B12 deficiency in over 16s: diagnosis and management | NG239 | | |
Endoscopic sleeve gastroplasty for obesity | IPG783 | | |
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations | TA952 | | |
Tuberculosis | NG33 | | |
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over | TA949 | | |
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over | TA950 | | |
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | | |
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments | TA947 | | |
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 | | |
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) | TA945 | | |
Caesarean birth | NG192 | | |
Pharyngeal electrical stimulation for neurogenic dysphagia | IPG781 | | |
Temperature control to improve neurological outcomes after cardiac arrest | IPG782 | | |
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | | |
Early and locally advanced breast cancer: diagnosis and management | NG101 | | |
Sebelipase alfa for treating Wolman disease | HST30 | | |
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | | |
Intravascular lithotripsy for calcified arteries in peripheral arterial disease | IPG780 | | |
Bipolar disorder: assessment and management | CG185 | | |
Targeted-release budesonide for treating primary IgA nephropathy | TA937 | | |
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) | TA940 | | |
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) | TA941 | | |
Empagliflozin for treating chronic kidney disease | TA942 | | |
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | | |
Risdiplam for treating spinal muscular atrophy | TA755 | | |
Middle meningeal artery embolisation for chronic subdural haematomas | IPG779 | | |
Cardiovascular disease: risk assessment and reduction, including lipid modification | NG238 | | |
Velmanase alfa for treating alpha-mannosidosis | HST29 | | |
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | TA939 | | |
Acne vulgaris: management | NG198 | | |
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) | TA938 | | |
Secukinumab for treating moderate to severe hidradenitis suppurativa | TA935 | | |
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) | TA936 | | |
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism | IPG778 | | |
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) | TA933 | | |
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms | TA934 | | |
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) | TA932 | | |
Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis | IPG777 | | |
Zanubrutinib for treating chronic lymphocytic leukaemia | TA931 | | |
Transient loss of consciousness ('blackouts') in over 16s | CG109 | | |
Hypertension in adults: diagnosis and management | NG136 | | |
Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management | NG237 | | |
Biodegradable subacromial spacer insertion for rotator cuff tears | IPG775 | | |
Extracorporeal carbon dioxide removal for acute respiratory failure | IPG776 | | |
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments | TA930 | | |
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | CG164 | | |
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA929 | | |
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine | TA928 | | |
Jaundice in newborn babies under 28 days | CG98 | | |
Pneumonia in adults: diagnosis and management | CG191 | | |
Ranibizumab for treating diabetic macular oedema | TA274 | | |
Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions | IPG774 | | |
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable | TA917 | | |
Tirzepatide for treating type 2 diabetes | TA924 | | |
Mirikizumab for treating moderately to severely active ulcerative colitis | TA925 | | |
Baricitinib for treating severe alopecia areata | TA926 | | |
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) | TA923 | | |
Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia | IPG773 | | |
Stroke rehabilitation in adults | NG236 | | |
Rimegepant for treating migraine | TA919 | | |
Tofacitinib for treating active ankylosing spondylitis | TA920 | | |
Ruxolitinib for treating polycythaemia vera | TA921 | | |
Daridorexant for treating long-term insomnia | TA922 | | |
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA927 | | |
Thyroid disease: assessment and management | NG145 | | |
Bimekizumab for treating axial spondyloarthritis | TA918 | | |
Pegunigalsidase alfa for treating Fabry disease | TA915 | | |
Bimekizumab for treating active psoriatic arthritis | TA916 | | |
Urinary incontinence in neurological disease: assessment and management | CG148 | | |
Ovarian cancer: recognition and initial management | CG122 | | |
Suspected cancer: recognition and referral | NG12 | | |
Suspected neurological conditions: recognition and referral | NG127 | | |
Hearing loss in adults: assessment and management | NG98 | | |
Intrapartum care | NG235 | | |
Acute kidney injury: prevention, detection and management | NG148 | | |
Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment | IPG772 | | |
Birch bark extract for treating epidermolysis bullosa | HST28 | | |
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency | TA914 | | |
Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG770 | | |
Cryotherapy for chronic rhinitis | IPG771 | | |
Cirrhosis in over 16s: assessment and management | NG50 | | |
Spinal metastases and metastatic spinal cord compression | NG234 | | |
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy | TA913 | | |
Semaglutide for managing overweight and obesity | TA875 | | |
Otitis media with effusion in under 12s | NG233 | | |
Ectopic pregnancy and miscarriage: diagnosis and initial management | NG126 | | |
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease | TA912 | | |
Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease | IPG769 | | |
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing | NG158 | | |
Obesity: identification, assessment and management | CG189 | | |
Afamelanotide for treating erythropoietic protoporphyria | HST27 | | |
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | TA911 | | |
KardiaMobile for detecting atrial fibrillation | MTG64 | | |
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) | TA910 | | |
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer | TA909 | | |
Irreversible electroporation for treating prostate cancer | IPG768 | | |
Rimegepant for preventing migraine | TA906 | | |
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy | TA908 | | |
Oesophago-gastric cancer: assessment and management in adults | NG83 | | |
Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention | IPG766 | | |
Radiofrequency denervation for osteoarthritic knee pain | IPG767 | | |
Deucravacitinib for treating moderate to severe plaque psoriasis | TA907 | | |
Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option | IPG764 | | |
Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people | IPG765 | | |
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA902 | | |
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer | TA903 | | |
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer | TA904 | | |
Upadacitinib for previously treated moderately to severely active Crohn's disease | TA905 | | |
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) | TA901 | | |
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer | TA898 | | |
Tixagevimab plus cilgavimab for preventing COVID-19 | TA900 | | |
Atopic eczema in under 12s: diagnosis and management | CG57 | | |
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma | TA894 | | |
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | TA895 | | |
Bulevirtide for treating chronic hepatitis D | TA896 | | |
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over | TA893 | | |
Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer | IPG763 | | |
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma | TA897 | | |
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) | TA899 | | |
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia | TA891 | | |
Mosunetuzumab for treating relapsed or refractory follicular lymphoma | TA892 | | |
Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries | IPG762 | | |
Head injury: assessment and early management | NG232 | | |
Risankizumab for previously treated moderately to severely active Crohn's disease | TA888 | | |
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA889 | | |
Difelikefalin for treating pruritus in people having haemodialysis | TA890 | | |
Diabetes (type 1 and type 2) in children and young people: diagnosis and management | NG18 | | |
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | TA886 | | |
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | TA887 | | |
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments | TA881 | | |
Voclosporin with mycophenolate mofetil for treating lupus nephritis | TA882 | | |
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma | TA883 | | |
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) | TA884 | | |
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management | CG104 | | |
Tezepelumab for treating severe asthma | TA880 | | |
Lumasiran for treating primary hyperoxaluria type 1 | HST25 | | |
Onasemnogene abeparvovec for treating spinal muscular atrophy | HST15 | | |
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency | HST26 | | |
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy | HST24 | | |
Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea | IPG760 | | |
Endoscopic ultrasound-guided biliary drainage for biliary obstruction | IPG761 | | |
Hypertension in pregnancy: diagnosis and management | NG133 | | |
AposHealth for knee osteoarthritis | MTG76 | | |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) | TA879 | | |
Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases | IPG759 | | |
Percutaneous thoracic duct embolisation for persistent chyle leak | IPG755 | | |
Focal therapy using high-intensity focused ultrasound for localised prostate cancer | IPG756 | | |
Maximal cytoreductive surgery for advanced ovarian cancer | IPG757 | | |
Radiofrequency ablation for palliation of painful spinal metastases | IPG758 | | |
UrgoStart for treating diabetic foot ulcers and leg ulcers | MTG42 | | |
Finerenone for treating chronic kidney disease in type 2 diabetes | TA877 | | |
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer | TA876 | | |
Asfotase alfa for treating paediatric-onset hypophosphatasia | HST23 | | |
Endoluminal gastroplication for gastro-oesophageal reflux disease | IPG753 | | |
Percutaneous transluminal renal sympathetic denervation for resistant hypertension | IPG754 | | |
Eptinezumab for preventing migraine | TA871 | | |
Cannabidiol for treating seizures caused by tuberous sclerosis complex | TA873 | | |
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | TA874 | | |
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | TA872 | | |
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene | HST22 | | |
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | TA870 | | |
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) | TA867 | | |
Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) | TA869 | | |
Vutrisiran for treating hereditary transthyretin-related amyloidosis | TA868 | | |
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management | NG231 | | |
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | TA865 | | |
Regorafenib for previously treated metastatic colorectal cancer | TA866 | | |
Transvenous obliteration for gastric varices | IPG751 | | |
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer | IPG752 | | |
Upadacitinib for treating active non-radiographic axial spondyloarthritis | TA861 | | |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | | |
Somatrogon for treating growth disturbance in children and young people aged 3 years and over | TA863 | | |
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted | TA864 | | |
Delirium: prevention, diagnosis and management in hospital and long-term care | CG103 | | |
Maribavir for treating refractory cytomegalovirus infection after transplant | TA860 | | |
Trabeculectomy with a biodegradable collagen matrix implant for glaucoma | IPG750 | | |
Tobacco: preventing uptake, promoting quitting and treating dependence | NG209 | | |
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) | TA859 | | |
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education | NG213 | | |
Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease | IPG749 | | |
Transcutaneous electrical stimulation of the trigeminal nerve for ADHD | IPG748 | | |
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma | TA857 | | |
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | TA858 | | |
Hip fracture: management | CG124 | | |
Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain | IPG747 | | |
Upadacitinib for treating moderately to severely active ulcerative colitis | TA856 | | |
Thyroid cancer: assessment and management | NG230 | | |
Avatrombopag for treating primary chronic immune thrombocytopenia | TA853 | | |
Fetal monitoring in labour | NG229 | | |
Cabozantinib for previously treated advanced hepatocellular carcinoma | TA849 | | |
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy | TA850 | | |
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | | |
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | | |
Esketamine nasal spray for treatment-resistant depression | TA854 | | |
Memokath 051 Ureter stent for ureteric obstruction | MTG75 | | |
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) | TA848 | | |
Optilume for treating recurrent bulbar urethral strictures | MTG73 | | |
GreenLight XPS for treating benign prostatic hyperplasia | MTG74 | | |
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) | TA845 | | |
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) | TA846 | | |
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA847 | | |
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) | TA844 | | |
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) | TA843 | | |
Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis | IPG746 | | |
Fractures (complex): assessment and management | NG37 | | |
Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management | NG228 | | |
Ab interno canaloplasty for open-angle glaucoma | IPG745 | | |
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA841 | | |
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) | TA842 | | |
Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules | IPG743 | | |
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) | TA839 | | |
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids
(terminated appraisal) | TA840 | | |
Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder | IPG742 | | |
Advocacy services for adults with health and social care needs | NG227 | | |
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) | TA838 | | |
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine | IPG740 | | |
YAG laser vitreolysis for symptomatic vitreous floaters | IPG741 | | |
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | TA837 | | |
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA836 | | |
Osteoarthritis in over 16s: diagnosis and management | NG226 | | |
Pembrolizumab for adjuvant treatment of renal cell carcinoma | TA830 | | |
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | TA832 | | |
Zanubrutinib for treating Waldenstrom's macroglobulinaemia | TA833 | | |
Fostamatinib for treating refractory chronic immune thrombocytopenia | TA835 | | |
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) | TA834 | | |
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer | MTG72 | | |
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy | TA827 | | |
Ozanimod for treating moderately to severely active ulcerative colitis | TA828 | | |
Upadacitinib for treating active ankylosing spondylitis | TA829 | | |
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA823 | | |
Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain | IPG739 | | |
Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG737 | | |
Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause | IPG738 | | |
Neuropad for detecting preclinical diabetic peripheral neuropathy | MTG38 | | |
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis | TA825 | | |
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) | TA826 | | |
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas | CG118 | | |
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) | TA822 | | |
Dexamethasone intravitreal implant for treating diabetic macular oedema | TA824 | | |
Self-harm: assessment, management and preventing recurrence | NG225 | | |
Faecal microbiota transplant for recurrent Clostridioides difficile infection | MTG71 | | |
Brolucizumab for treating diabetic macular oedema | TA820 | | |
iFuse for treating chronic sacroiliac joint pain | MTG39 | | |
Focal resurfacing implants to treat articular cartilage damage in the knee | IPG734 | | |
Transcutaneous electrical neuromuscular stimulation for urinary incontinence | IPG735 | | |
Superficial venous arterialisation for chronic limb threatening ischaemia | IPG736 | | |
Avalglucosidase alfa for treating Pompe disease | TA821 | | |
Type 1 diabetes in adults: diagnosis and management | NG17 | | |
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | | |
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | TA818 | | |
SecurAcath for securing percutaneous catheters | MTG34 | | |
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA815 | | |
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | | |
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | | |
Bioresorbable stent implantation to treat coronary artery disease | IPG732 | | |
Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection | IPG733 | | |
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer | TA812 | | |
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | TA813 | | |
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis | TA814 | | |
Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation | IPG730 | | |
Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation | IPG731 | | |
Melanoma: assessment and management | NG14 | | |
Urinary tract infection in under 16s: diagnosis and management | NG224 | | |
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) | TA811 | | |
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease | TA809 | | |
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | | |
PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites | MTG9 | | |
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA803 | | |
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides | TA805 | | |
Belimumab for treating lupus nephritis (terminated appraisal) | TA806 | | |
Roxadustat for treating symptomatic anaemia in chronic kidney disease | TA807 | | |
Fenfluramine for treating seizures associated with Dravet syndrome | TA808 | | |
Setmelanotide for treating obesity caused by LEPR or POMC deficiency | HST21 | | |
Social, emotional and mental wellbeing in primary and secondary education | NG223 | | |
MiraQ for assessing graft flow during coronary artery bypass graft surgery | MTG8 | | |
Teduglutide for treating short bowel syndrome | TA804 | | |
Vertebral body tethering for idiopathic scoliosis in children and young people | IPG728 | | |
Nerve graft for corneal denervation | IPG729 | | |
Depression in adults: treatment and management | NG222 | | |
Type 2 diabetes in adults: management | NG28 | | |
Faricimab for treating diabetic macular oedema | TA799 | | |
Faricimab for treating wet age-related macular degeneration | TA800 | | |
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | | |
Cemiplimab for treating advanced cutaneous squamous cell carcinoma | TA802 | | |
Multiple sclerosis in adults: management | NG220 | | |
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation | TA798 | | |
Reducing sexually transmitted infections | NG221 | | |
Venetoclax for treating chronic lymphocytic leukaemia | TA796 | | |
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | | |
Preterm labour and birth | NG25 | | |
Gout: diagnosis and management | NG219 | | |
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) | TA793 | | |
Diroximel fumarate for treating relapsing–remitting multiple sclerosis | TA794 | | |
Ibrutinib for treating Waldenstrom's macroglobulinaemia | TA795 | | |
Peristeen Plus transanal irrigation system for managing bowel dysfunction | MTG36 | | |
Thopaz+ portable digital system for managing chest drains | MTG37 | | |
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) | IPG727 | | |
Filgotinib for treating moderately to severely active ulcerative colitis | TA792 | | |
Social work with adults experiencing complex needs | NG216 | | |
Endoanchoring systems in endovascular aortic aneurysm repair | IPG725 | | |
Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis | IPG726 | | |
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) | TA790 | | |
Romosozumab for treating severe osteoporosis | TA791 | | |
Sleepio to treat insomnia and insomnia symptoms | MTG70 | | |
Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome | IPG724 | | |
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations | TA789 | | |
Vaccine uptake in the general population | NG218 | | |
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy | TA788 | | |
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over | HST20 | | |
Liposuction for chronic lymphoedema | IPG723 | | |
Epilepsies in children, young people and adults | NG217 | | |
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies | TA786 | | |
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA787 | | |
Elosulfase alfa for treating mucopolysaccharidosis type 4A | HST19 | | |
Intramedullary distraction for upper limb lengthening | IPG722 | | |
Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults | NG215 | | |
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | TA784 | | |
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) | TA785 | | |
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management | NG128 | | |
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma | TA783 | | |
myCOPD for managing chronic obstructive pulmonary disease | MTG68 | | |
UroShield for preventing catheter-associated urinary tract infections | MTG69 | | |
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer | TA781 | | |
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) | TA782 | | |
Liposuction for chronic lipoedema | IPG721 | | |
Atidarsagene autotemcel for treating metachromatic leukodystrophy | HST18 | | |
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma | TA780 | | |
Integrated health and social care for people experiencing homelessness | NG214 | | |
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA779 | | |
Otitis media (acute): antimicrobial prescribing | NG91 | | |
Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis | IPG720 | | |
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA774 | | |
Empagliflozin for treating chronic heart failure with reduced ejection fraction | TA773 | | |
Dapagliflozin for treating chronic kidney disease | TA775 | | |
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA776 | | |
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA777 | | |
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria | TA778 | | |
Prontosan for treating acute and chronic wounds | MTG67 | | |
3C Patch for treating diabetic foot ulcers | MTG66 | | |
Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach | IPG717 | | |
Intramedullary distraction for lower limb lengthening | IPG718 | | |
Endoscopic balloon dilation for subglottic or tracheal stenosis | IPG719 | | |
Mental wellbeing at work | NG212 | | |
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies | TA772 | | |
Odevixibat for treating progressive familial intrahepatic cholestasis | HST17 | | |
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer | TA770 | | |
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) | TA771 | | |
Stereotactic radiosurgery for trigeminal neuralgia | IPG715 | | |
Microwave ablation for primary or metastatic cancer in the lung | IPG716 | | |
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) | TA762 | | |
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable | TA763 | | |
Fremanezumab for preventing migraine | TA764 | | |
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA765 | | |
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | TA766 | | |
Ponesimod for treating relapsing–remitting multiple sclerosis | TA767 | | |
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA768 | | |
Palforzia for treating peanut allergy in children and young people | TA769 | | |
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care | MTG65 | | |
Glaucoma: diagnosis and management | NG81 | | |
Sodium zirconium cyclosilicate for treating hyperkalaemia | TA599 | | |
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA761 | | |
Rehabilitation after traumatic injury | NG211 | | |
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA760 | | |
Cabotegravir with rilpivirine for treating HIV-1 | TA757 | | |
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy | TA758 | | |
Headaches in over 12s: diagnosis and management | CG150 | | |
Endo-SPONGE for treating low rectal anastomotic leak | MTG63 | | |
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA756 | | |
Transanal total mesorectal excision for rectal cancer | IPG713 | | |
Endobronchial nerve ablation for chronic obstructive pulmonary disease | IPG714 | | |
Colorectal cancer | NG151 | | |
Prostate cancer: diagnosis and management | NG131 | | |
Belimumab for treating active autoantibody-positive systemic lupus erythematosus | TA752 | | |
Cenobamate for treating focal onset seizures in epilepsy | TA753 | | |
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome | TA754 | | |
ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections | MTG62 | | |
Pelvic floor dysfunction: prevention and non-surgical management | NG210 | | |
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | | |
Dupilumab for treating severe asthma with type 2 inflammation | TA751 | | |
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders | TA748 | | |
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) | TA749 | | |
Synergo for non-muscle-invasive bladder cancer | MTG61 | | |
Fever in under 5s: assessment and initial management | NG143 | | |
Givosiran for treating acute hepatic porphyria | HST16 | | |
Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure | IPG711 | | |
Coronary sinus narrowing device implantation for refractory angina | IPG712 | | |
Chronic kidney disease: assessment and management | NG203 | | |
Acute heart failure: diagnosis and management | CG187 | | |
Heart valve disease presenting in adults: investigation and management | NG208 | | |
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | | |
Nintedanib for treating progressive fibrosing interstitial lung diseases | TA747 | | |
Upadacitinib for treating moderate rheumatoid arthritis | TA744 | | |
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) | TA745 | | |
Inducing labour | NG207 | | |
Selpercatinib for treating advanced thyroid cancer with RET alterations | TA742 | | |
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management | NG206 | | |
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | | |
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | | |
Genicular artery embolisation for pain from knee osteoarthritis | IPG708 | | |
Laparoscopic renal denervation for loin pain haematuria syndrome | IPG709 | | |
Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access | IPG710 | | |
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | | |
Looked-after children and young people | NG205 | | |
Tofacitinib for treating juvenile idiopathic arthritis | TA735 | | |
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy | TA736 | | |
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
Berotralstat for preventing recurrent attacks of hereditary angioedema | TA738 | | |
Secukinumab for treating moderate to severe plaque psoriasis in children and young people | TA734 | | |
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) | TA732 | | |
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA733 | | |
DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography | MTG60 | | |
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) | TA730 | | |
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) | TA731 | | |
Lateral elbow resurfacing for arthritis | IPG705 | | |
Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis | IPG706 | | |
Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair | IPG707 | | |
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA726 | | |
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA727 | | |
Midostaurin for treating advanced systemic mastocytosis | TA728 | | |
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria | TA729 | | |
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | | |
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer | TA724 | | |
Bimekizumab for treating moderate to severe plaque psoriasis | TA723 | | |
Magnetic resonance therapy for knee osteoarthritis | IPG702 | | |
Laparoscopic removal of uterine fibroids with power morcellation | IPG703 | | |
Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids | IPG704 | | |
Babies, children and young people's experience of healthcare | NG204 | | |
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA722 | | |
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s | NG202 | | |
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome | TA139 | | |
Antenatal care | NG201 | | |
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | TA720 | | |
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | | |
Bronchiolitis in children: diagnosis and management | NG9 | | |
Inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage | IPG701 | | |
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | | |
Clostridioides difficile infection: antimicrobial prescribing | NG199 | | |
ENDURALIFE powered CRT-D devices for treating heart failure | MTG33 | | |
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) | TA717 | | |
Ixekizumab for treating axial spondyloarthritis | TA718 | | |
Secukinumab for treating non-radiographic axial spondyloarthritis | TA719 | | |
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA714 | | |
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | | |
Enzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | | |
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy | TA713 | | |
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA275 | | |
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | TA249 | | |
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | TA256 | | |
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA355 | | |
Atrial fibrillation: diagnosis and management | NG196 | | |
Plus Sutures for preventing surgical site infection | MTG59 | | |
Laser lithotripsy for difficult-to-treat bile duct stones | IPG699 | | |
Percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve | IPG700 | | |
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis | TA708 | | |
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | | |
Ravulizumab for treating atypical haemolytic uraemic syndrome | TA710 | | |
Patient experience in adult NHS services: improving the experience of care for people using adult NHS services | CG138 | | |
Shared decision making | NG197 | | |
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | | |
Autism spectrum disorder in adults: diagnosis and management | CG142 | | |
Autism spectrum disorder in under 19s: support and management | CG170 | | |
Ozanimod for treating relapsing–remitting multiple sclerosis | TA706 | | |
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer | TA705 | | |
Electrohydraulic lithotripsy for difficult-to-treat bile duct stones | IPG698 | | |
Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant | IPG695 | | |
Transvaginal laser therapy for stress urinary incontinence | IPG696 | | |
Transvaginal laser therapy for urogenital atrophy | IPG697 | | |
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) | TA702 | | |
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) | TA703 | | |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | | |
Heavy menstrual bleeding: assessment and management | NG88 | | |
HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography | MTG32 | | |
Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers | MTG20 | | |
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria | TA698 | | |
Ofatumumab for treating relapsing multiple sclerosis | TA699 | | |
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) | TA701 | | |
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy | TA696 | | |
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |
Permanent His-bundle pacemaker implantation for treating heart failure | IPG694 | | |
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia | MTG58 | | |
Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma | IPG692 | | |
Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults | IPG693 | | |
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA692 | | |
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA694 | | |
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma | TA695 | | |
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver | IPG691 | | |
Avelumab for treating metastatic Merkel cell carcinoma | TA517 | | |
Acalabrutinib for treating chronic lymphocytic leukaemia | TA689 | | |
Avelumab for untreated metastatic Merkel cell carcinoma | TA691 | | |
Postnatal care | NG194 | | |
Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain | NG193 | | |
Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids | IPG689 | | |
Extracorporeal whole liver perfusion for acute liver failure | IPG690 | | |
Danis stent for acute oesophageal variceal bleeding | MTG57 | | |
Anakinra for treating Still's disease | TA685 | | |
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA686 | | |
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA687 | | |
Selective internal radiation therapies for treating hepatocellular carcinoma | TA688 | | |
Cannabis-based medicinal products | NG144 | | |
Asthma: diagnosis, monitoring and chronic asthma management | NG80 | | |
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease | TA684 | | |
Erenumab for preventing migraine | TA682 | | |
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer | TA683 | | |
Alpha-Stim AID for anxiety disorders | MTG56 | | |
Free-functioning gracilis transfer to restore upper limb function in brachial plexus injury | IPG687 | | |
Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis | IPG688 | | |
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma | TA680 | | |
Baricitinib for treating moderate to severe atopic dermatitis | TA681 | | |
Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing | NG190 | | |
Safeguarding adults in care homes | NG189 | | |
Metreleptin for treating lipodystrophy | HST14 | | |
Filgotinib for treating moderate to severe rheumatoid arthritis | TA676 | | |
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma | TA677 | | |
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA678 | | |
Dapagliflozin for treating chronic heart failure with reduced ejection fraction | TA679 | | |
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA673 | | |
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | TA674 | | |
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) | TA675 | | |
Trabectedin for the treatment of advanced soft tissue sarcoma | TA185 | | |
Leukomed Sorbact for preventing surgical site infection | MTG55 | | |
Mepolizumab for treating severe eosinophilic asthma | TA671 | | |
Brolucizumab for treating wet age-related macular degeneration | TA672 | | |
Brain tumours (primary) and brain metastases in over 16s | NG99 | | |
Self-expanding implant insertion into the intersphincteric space for faecal incontinence | IPG685 | | |
Minimally invasive radical hysterectomy for early stage cervical cancer | IPG686 | | |
The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal | MTG54 | | |
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor | TA670 | | |
The PLASMA system for transurethral resection and haemostasis of the prostate | MTG53 | | |
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer | TA668 | | |
Pancreatitis | NG104 | | |
Diabetes in pregnancy: management from preconception to the postnatal period | NG3 | | |
Eating disorders: recognition and treatment | NG69 | | |
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma | TA666 | | |
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura | TA667 | | |
Peripheral arterial disease: diagnosis and management | CG147 | | |
Low back pain and sciatica in over 16s: assessment and management | NG59 | | |
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia | TA663 | | |
Liraglutide for managing overweight and obesity | TA664 | | |
Upadacitinib for treating severe rheumatoid arthritis | TA665 | | |
Zio XT for detecting cardiac arrhythmias | MTG52 | | |
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer | TA660 | | |
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma | TA661 | | |
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) | TA662 | | |
Swallowable gastric balloon capsule for weight loss | IPG684 | | |
Acute coronary syndromes | NG185 | | |
Drug-eluting stents for the treatment of coronary artery disease | TA152 | | |
Guidance on the use of coronary artery stents | TA71 | | |
Siponimod for treating secondary progressive multiple sclerosis | TA656 | | |
Carfilzomib for previously treated multiple myeloma | TA657 | | |
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma | TA658 | | |
Galcanezumab for preventing migraine | TA659 | | |
Human and animal bites: antimicrobial prescribing | NG184 | | |
Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis | IPG681 | | |
Balloon cryoablation for Barrett's oesophagus | IPG682 | | |
Balloon cryoablation for squamous dysplasia of the oesophagus | IPG683 | | |
Volanesorsen for treating familial chylomicronaemia syndrome | HST13 | | |
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy | TA655 | | |
SEM Scanner 200 for preventing pressure ulcers | MTG51 | | |
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer | TA653 | | |
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA654 | | |
Rheumatoid arthritis in adults: management | NG100 | | |
Behaviour change: digital and mobile health interventions | NG183 | | |
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma | TA650 | | |
Naldemedine for treating opioid-induced constipation | TA651 | | |
Transcranial magnetic stimulation for auditory hallucinations | IPG680 | | |
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma | TA649 | | |
Neuropathic pain in adults: pharmacological management in non-specialist settings | CG173 | | |
Insect bites and stings: antimicrobial prescribing | NG182 | | |
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA648 | | |
Axonics sacral neuromodulation system for treating refractory overactive bladder | MTG50 | | |
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) | TA646 | | |
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) | TA647 | | |
Avelumab with axitinib for untreated advanced renal cell carcinoma | TA645 | | |
Anaphylaxis: assessment and referral after emergency treatment | CG134 | | |
Perioperative care in adults | NG180 | | |
Rehabilitation for adults with complex psychosis | NG181 | | |
Surgical site infections: prevention and treatment | NG125 | | |
Deep brain stimulation for refractory epilepsy in adults | IPG678 | | |
Implanted vagus nerve stimulation for treatment-resistant depression | IPG679 | | |
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma | TA641 | | |
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia | TA642 | | |
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer | TA643 | | |
Entrectinib for treating NTRK fusion-positive solid tumours | TA644 | | |
Transcranial magnetic stimulation for obsessive-compulsive disorder | IPG676 | | |
Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease | IPG677 | | |
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant | TA640 | | |
Artificial iris insertion for acquired aniridia | IPG674 | | |
Artificial iris insertion for congenital aniridia | IPG675 | | |
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA638 | | |
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | TA639 | | |
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA634 | | |
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) | TA635 | | |
Eculizumab for treating refractory myasthenia gravis (terminated appraisal) | TA636 | | |
Ranibizumab for treating diabetic retinopathy (terminated appraisal) | TA637 | | |
Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention | IPG673 | | |
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia | MTG49 | | |
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA626 | | |
Ustekinumab for treating moderately to severely active ulcerative colitis | TA633 | | |
Generalised anxiety disorder and panic disorder in adults: management | CG113 | | |
Intravenous fluid therapy in children and young people in hospital | NG29 | | |
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer | TA632 | | |
Joint replacement (primary): hip, knee and shoulder | NG157 | | |
Larotrectinib for treating NTRK fusion-positive solid tumours | TA630 | | |
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer | TA628 | | |
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab | TA629 | | |
PneuX to prevent ventilator-associated pneumonia | MTG48 | | |
Lenalidomide with rituximab for previously treated follicular lymphoma | TA627 | | |
Abdominal aortic aneurysm: diagnosis and management | NG156 | | |
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis | TA312 | | |
Tinnitus: assessment and management | NG155 | | |
Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse | IPG669 | | |
Cyanoacrylate glue occlusion for varicose veins | IPG670 | | |
MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy | IPG671 | | |
Selective internal radiation therapy for unresectable colorectal metastases in the liver | IPG672 | | |
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) | TA625 | | |
Impetigo: antimicrobial prescribing | NG153 | | |
Neonatal parenteral nutrition | NG154 | | |
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis | TA624 | | |
Patiromer for treating hyperkalaemia | TA623 | | |
Sotagliflozin with insulin for treating type 1 diabetes | TA622 | | |
Antenatal and postnatal mental health: clinical management and service guidance | CG192 | | |
Episcissors-60 for mediolateral episiotomy | MTG47 | | |
Leg ulcer infection: antimicrobial prescribing | NG152 | | |
Fetoscopic prenatal repair for open neural tube defects in the fetus | IPG667 | | |
Open prenatal repair for open neural tube defects in the fetus | IPG668 | | |
Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues | IPG666 | | |
Supporting adult carers | NG150 | | |
Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C | MTG27 | | |
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) | TA618 | | |
Indoor air quality at home | NG149 | | |
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA617 | | |
Cladribine for treating relapsing–remitting multiple sclerosis | TA616 | | |
Balloon dilation for chronic eustachian tube dysfunction | IPG665 | | |
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome | TA614 | | |
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome | TA615 | | |
Menopause: diagnosis and management | NG23 | | |
gammaCore for cluster headache | MTG46 | | |
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 | HST12 | | |
Irreversible electroporation for primary liver cancer | IPG664 | | |
Diverticular disease: diagnosis and management | NG147 | | |
Workplace health: long-term sickness absence and capability to work | NG146 | | |
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab | TA612 | | |
Pentosan polysulfate sodium for treating bladder pain syndrome | TA610 | | |
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA611 | | |
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) | TA608 | | |
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) | TA609 | | |
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management | CG184 | | |
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease | TA607 | | |
Midcarpal hemiarthroplasty for wrist arthritis | IPG663 | | |
End of life care for adults: service delivery | NG142 | | |
Lanadelumab for preventing recurrent attacks of hereditary angioedema | TA606 | | |
Diabetic foot problems: prevention and management | NG19 | | |
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations | HST11 | | |
Gastro-oesophageal reflux disease in children and young people: diagnosis and management | NG1 | | |
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea | TA605 | | |
EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing | MTG12 | | |
Familial hypercholesterolaemia: identification and management | CG71 | | |
Idelalisib for treating refractory follicular lymphoma | TA604 | | |
Cellulitis and erysipelas: antimicrobial prescribing | NG141 | | |
High-intensity focused ultrasound for glaucoma | IPG661 | | |
Bioprosthetic plug insertion for anal fistula | IPG662 | | |
Abortion care | NG140 | | |
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA602 | | |
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA603 | | |
Tegaderm CHG securement dressing for vascular access sites in critically ill adults | MTG25 | | |
Pneumonia (community-acquired): antimicrobial prescribing | NG138 | | |
Pneumonia (hospital-acquired): antimicrobial prescribing | NG139 | | |
Attention deficit hyperactivity disorder: diagnosis and management | NG87 | | |
Implant insertion for prominent ears | IPG660 | | |
Benralizumab for treating severe eosinophilic asthma | TA565 | | |
Risankizumab for treating moderate to severe plaque psoriasis | TA596 | | |
Patisiran for treating hereditary transthyretin amyloidosis | HST10 | | |
Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms | IPG658 | | |
Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer | IPG659 | | |
Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) | TA594 | | |
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA595 | | |
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism | NG89 | | |
Alcohol interventions in secondary and further education | NG135 | | |
PICO negative pressure wound dressings for closed surgical incisions | MTG43 | | |
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis | TA590 | | |
Letermovir for preventing cytomegalovirus disease after a stem cell transplant | TA591 | | |
Chronic obstructive pulmonary disease in over 16s: diagnosis and management | NG115 | | |
End of life care for infants, children and young people with life-limiting conditions: planning and management | NG61 | | |
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer | IPG656 | | |
Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids | IPG657 | | |
Nusinersen for treating spinal muscular atrophy | TA588 | | |
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity | TA589 | | |
Motor neurone disease: assessment and management | NG42 | | |
Bisphosphonates for treating osteoporosis | TA464 | | |
Long-acting reversible contraception | CG30 | | |
Cardiac contractility modulation device implantation for heart failure | IPG655 | | |
Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction | IPG653 | | |
Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia | IPG654 | | |
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality | TA322 | | |
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies | TA171 | | |
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib | TA586 | | |
Lenalidomide plus dexamethasone for previously untreated multiple myeloma | TA587 | | |
Depression in children and young people: identification and management | NG134 | | |
Urinary incontinence and pelvic organ prolapse in women: management | NG123 | | |
Ambu aScope4 Broncho for use in unexpected difficult airways | MTG14 | | |
Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI | IPG650 | | |
Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg | IPG651 | | |
Bronchoscopic thermal vapour ablation for upper-lobe emphysema | IPG652 | | |
Ocrelizumab for treating primary progressive multiple sclerosis | TA585 | | |
Endocuff Vision for assisting visualisation during colonoscopy | MTG45 | | |
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes | TA583 | | |
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer | TA584 | | |
The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters | MTG24 | | |
Therapeutic hypothermia for acute ischaemic stroke | IPG647 | | |
Collagen paste for closing an anal fistula | IPG648 | | |
Percutaneous mitral valve leaflet repair for mitral regurgitation | IPG649 | | |
Hyperparathyroidism (primary): diagnosis, assessment and initial management | NG132 | | |
Inotersen for treating hereditary transthyretin amyloidosis | HST9 | | |
Enzalutamide for hormone-relapsed non-metastatic prostate cancer | TA580 | | |
Curos for preventing infections when using needleless connectors | MTG44 | | |
Crohn's disease: management | NG129 | | |
Ulcerative colitis: management | NG130 | | |
Intrapartum care for women with existing medical conditions or obstetric complications and their babies | NG121 | | |
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma | TA577 | | |
Endoscopic ablation for an anal fistula | IPG645 | | |
Endoscopic ablation for a pilonidal sinus | IPG646 | | |
Certolizumab pegol for treating moderate to severe plaque psoriasis | TA574 | | |
Tildrakizumab for treating moderate to severe plaque psoriasis | TA575 | | |
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) | TA576 | | |
Specialist neonatal respiratory care for babies born preterm | NG124 | | |
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes | TA572 | | |
The Debrisoft monofilament debridement pad for use in acute or chronic wounds | MTG17 | | |
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib | TA571 | | |
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) | TA570 | | |
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer | TA569 | | |
Radially emitting laser fibre treatment of an anal fistula | IPG644 | | |
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) | TA568 | | |
Cochlear implants for children and adults with severe to profound deafness | TA566 | | |
High-intensity focused ultrasound for symptomatic benign thyroid nodules | IPG643 | | |
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia | TA561 | | |
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma | TA562 | | |
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA563 | | |
Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal | IPG642 | | |
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) | TA560 | | |
Cough (acute): antimicrobial prescribing | NG120 | | |
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer | IPG638 | | |
Laparoscopic cerclage for cervical incompetence to prevent late miscarriage or preterm birth | IPG639 | | |
Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis | IPG640 | | |
Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain | MTG41 | | |
Platelet-rich plasma injections for knee osteoarthritis | IPG637 | | |
Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation | IPG636 | | |
Cerebral palsy in adults | NG119 | | |
Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers | MTG40 | | |
Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms | MTG10 | | |
Regorafenib for previously treated advanced hepatocellular carcinoma | TA555 | | |
Darvadstrocel for treating complex perianal fistulas in Crohn's disease | TA556 | | |
Renal and ureteric stones: assessment and management | NG118 | | |
Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults | IPG634 | | |
Bronchial thermoplasty for severe asthma | IPG635 | | |
Lenvatinib for untreated advanced hepatocellular carcinoma | TA551 | | |
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia | TA552 | | |
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing | NG117 | | |
Vandetanib for treating medullary thyroid cancer | TA550 | | |
Post-traumatic stress disorder | NG116 | | |
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing | NG114 | | |
Decitabine for untreated acute myeloid leukaemia (terminated appraisal) | TA548 | | |
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) | TA549 | | |
Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain | IPG632 | | |
Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions | IPG633 | | |
Tofacitinib for moderately to severely active ulcerative colitis | TA547 | | |
Urinary tract infection (catheter-associated): antimicrobial prescribing | NG113 | | |
Padeliporfin for untreated localised prostate cancer | TA546 | | |
Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis | IPG631 | | |
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia | TA545 | | |
Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma | IPG630 | | |
Urinary tract infection (lower): antimicrobial prescribing | NG109 | | |
Prostatitis (acute): antimicrobial prescribing | NG110 | | |
Pyelonephritis (acute): antimicrobial prescribing | NG111 | | |
Urinary tract infection (recurrent): antimicrobial prescribing | NG112 | | |
Eltrombopag for treating chronic immune thrombocytopenia | TA293 | | |
Romiplostim for the treatment of chronic immune thrombocytopenia | TA221 | | |
Myeloma: diagnosis and management | NG35 | | |
Lyme disease | NG95 | | |
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma | TA544 | | |
Burosumab for treating X-linked hypophosphataemia in children and young people | HST8 | | |
Renal replacement therapy and conservative management | NG107 | | |
Decision-making and mental capacity | NG108 | | |
Cabozantinib for untreated advanced renal cell carcinoma | TA542 | | |
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA543 | | |
E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta | MTG16 | | |
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer | IPG628 | | |
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia | TA541 | | |
Chronic heart failure in adults: diagnosis and management | NG106 | | |
Preventing suicide in community and custodial settings | NG105 | | |
Leadless cardiac pacemaker implantation for bradyarrhythmias | IPG626 | | |
Superior rectal artery embolisation for haemorrhoids | IPG627 | | |
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours | TA539 | | |
Sutureless aortic valve replacement for aortic stenosis | IPG624 | | |
Flu vaccination: increasing uptake | NG103 | | |
Dinutuximab beta for treating neuroblastoma | TA538 | | |
Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG625 | | |
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | | |
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | | |
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA537 | | |
Community pharmacies: promoting health and wellbeing | NG102 | | |
Dupilumab for treating moderate to severe atopic dermatitis | TA534 | | |
Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing | IPG621 | | |
Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing | IPG622 | | |
Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures | IPG623 | | |
Superior capsular augmentation for massive rotator cuff tears | IPG619 | | |
Transaxial interbody lumbosacral fusion for severe chronic low back pain | IPG620 | | |
Ocrelizumab for treating relapsing–remitting multiple sclerosis | TA533 | | |
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | TA531 | | |
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA529 | | |
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy | TA530 | | |
Beta interferons and glatiramer acetate for treating multiple sclerosis | TA527 | | |
Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor | IPG617 | | |
Laparoscopic ventral mesh rectopexy for internal rectal prolapse | IPG618 | | |
Dementia: assessment, management and support for people living with dementia and their carers | NG97 | | |
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | TA217 | | |
Intranasal phototherapy for allergic rhinitis | IPG616 | | |
Guselkumab for treating moderate to severe plaque psoriasis | TA521 | | |
Midostaurin for untreated acute myeloid leukaemia | TA523 | | |
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma | TA524 | | |
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA525 | | |
Arsenic trioxide for treating acute promyelocytic leukaemia | TA526 | | |
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over | NG36 | | |
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer | IPG614 | | |
Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy | IPG615 | | |
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy | TA520 | | |
Percutaneous balloon valvuloplasty for fetal critical aortic stenosis | IPG613 | | |
Robot-assisted kidney transplant | IPG609 | | |
Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG611 | | |
Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma | IPG612 | | |
Nerve transfer to partially restore upper limb function in tetraplegia | IPG610 | | |
Tocilizumab for treating giant cell arteritis | TA518 | | |
Care and support of people growing older with learning disabilities | NG96 | | |
Learning disabilities and behaviour that challenges: service design and delivery | NG93 | | |
Emergency and acute medical care in over 16s: service delivery and organisation | NG94 | | |
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen | TA515 | | |
Cabozantinib for treating medullary thyroid cancer | TA516 | | |
Physical activity and the environment | NG90 | | |
Brodalumab for treating moderate to severe plaque psoriasis | TA511 | | |
Tivozanib for treating advanced renal cell carcinoma | TA512 | | |
Obinutuzumab for untreated advanced follicular lymphoma | TA513 | | |
Mosaicplasty for symptomatic articular cartilage defects of the knee | IPG607 | | |
Laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina | IPG608 | | |
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee | TA508 | | |
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer | TA509 | | |
Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease | IPG606 | | |
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C | TA507 | | |
People's experience in adult social care services: improving the experience of care and support for people using adult social care services | NG86 | | |
Aortic valve reconstruction with processed bovine pericardium | IPG604 | | |
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency | HST7 | | |
Pancreatic cancer in adults: diagnosis and management | NG85 | | |
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women | TA160 | | |
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women | TA161 | | |
Pirfenidone for treating idiopathic pulmonary fibrosis | TA504 | | |
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer | TA501 | | |
Ibrutinib for treating relapsed or refractory mantle cell lymphoma | TA502 | | |
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer | TA503 | | |
Sore throat (acute): antimicrobial prescribing | NG84 | | |
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma | TA498 | | |
Glecaprevir–pibrentasvir for treating chronic hepatitis C | TA499 | | |
Ceritinib for untreated ALK-positive non-small-cell lung cancer | TA500 | | |
Age-related macular degeneration | NG82 | | |
Golimumab for treating non-radiographic axial spondyloarthritis | TA497 | | |
Autism spectrum disorder in under 19s: recognition, referral and diagnosis | CG128 | | |
Endobronchial valve insertion to reduce lung volume in emphysema | IPG600 | | |
Transcutaneous microwave ablation for severe primary axillary hyperhidrosis | IPG601 | | |
Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure | IPG602 | | |
Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death | IPG603 | | |
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA495 | | |
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA496 | | |
Transvaginal mesh repair of anterior or posterior vaginal wall prolapse | IPG599 | | |
Naltrexone–bupropion for managing overweight and obesity | TA494 | | |
Processed nerve allografts to repair peripheral nerve discontinuities | IPG597 | | |
Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea | IPG598 | | |
Vismodegib for treating basal cell carcinoma | TA489 | | |
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane | TA458 | | |
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours | TA488 | | |
Total distal radioulnar joint replacement for symptomatic joint instability or arthritis | IPG595 | | |
Extracranial to intracranial bypass for intracranial atherosclerosis | IPG596 | | |
Sarilumab for moderate to severe rheumatoid arthritis | TA485 | | |
Aflibercept for treating choroidal neovascularisation | TA486 | | |
Sinusitis (acute): antimicrobial prescribing | NG79 | | |
Cataracts in adults: management | NG77 | | |
Cystic fibrosis: diagnosis and management | NG78 | | |
Hepatitis B (chronic): diagnosis and management | CG165 | | |
Tofacitinib for moderate to severe rheumatoid arthritis | TA480 | | |
Immunosuppressive therapy for kidney transplant in adults | TA481 | | |
Immunosuppressive therapy for kidney transplant in children and young people | TA482 | | |
Child maltreatment: when to suspect maltreatment in under 18s | CG89 | | |
Child abuse and neglect | NG76 | | |
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee | TA477 | | |
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma | TA478 | | |
Reslizumab for treating severe eosinophilic asthma | TA479 | | |
Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease | IPG593 | | |
Faltering growth: recognition and management of faltering growth in children | NG75 | | |
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | TA439 | | |
Intermediate care including reablement | NG74 | | |
Type 2 diabetes: prevention in people at high risk | PH38 | | |
Ab externo canaloplasty for primary open-angle glaucoma | IPG591 | | |
High-intensity focused ultrasound for symptomatic breast fibroadenoma | IPG592 | | |
Pembrolizumab for advanced melanoma not previously treated with ipilimumab | TA366 | | |
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy | TA428 | | |
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab | TA357 | | |
Fertility problems: assessment and treatment | CG156 | | |
Sorafenib for treating advanced hepatocellular carcinoma | TA474 | | |
Dimethyl fumarate for treating moderate to severe plaque psoriasis | TA475 | | |
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | TA476 | | |
Psoriasis: assessment and management | CG153 | | |
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck | TA473 | | |
Vitamin D: supplement use in specific population groups | PH56 | | |
Radiofrequency treatment for haemorrhoids | IPG589 | | |
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) | TA468 | | |
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) | TA469 | | |
Advanced breast cancer: diagnosis and treatment | CG81 | | |
Holoclar for treating limbal stem cell deficiency after eye burns | TA467 | | |
Pemetrexed for the maintenance treatment of non-small-cell lung cancer | TA190 | | |
Developmental follow-up of children and young people born preterm | NG72 | | |
Cabozantinib for previously treated advanced renal cell carcinoma | TA463 | | |
Baricitinib for moderate to severe rheumatoid arthritis | TA466 | | |
moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment | MTG2 | | |
Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition | CG32 | | |
Transcatheter aortic valve implantation for aortic stenosis | IPG586 | | |
Adalimumab and dexamethasone for treating non-infectious uveitis | TA460 | | |
Roflumilast for treating chronic obstructive pulmonary disease | TA461 | | |
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma | TA462 | | |
Parkinson's disease in adults | NG71 | | |
Constipation in children and young people: diagnosis and management | CG99 | | |
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people | TA455 | | |
Ustekinumab for moderately to severely active Crohn's disease after previous treatment | TA456 | | |
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) | TA452 | | |
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) | TA453 | | |
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA454 | | |
Air pollution: outdoor air quality and health | NG70 | | |
Eliglustat for treating type 1 Gaucher disease | HST5 | | |
Infracoccygeal sacropexy using mesh to repair vaginal vault prolapse | IPG581 | | |
Infracoccygeal sacropexy using mesh to repair uterine prolapse | IPG582 | | |
Sacrocolpopexy using mesh to repair vaginal vault prolapse | IPG583 | | |
Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse | IPG584 | | |
Etelcalcetide for treating secondary hyperparathyroidism | TA448 | | |
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease | TA449 | | |
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia | TA450 | | |
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia | TA451 | | |
Obesity: working with local communities | PH42 | | |
Spondyloarthritis in over 16s: diagnosis and management | NG65 | | |
Endoscopic full thickness removal of non-lifting colonic polyps | IPG580 | | |
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA444 | | |
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA445 | | |
Idiopathic pulmonary fibrosis in adults: diagnosis and management | CG163 | | |
Intravenous fluid therapy in adults in hospital | CG174 | | |
Irreversible electroporation for treating pancreatic cancer | IPG579 | | |
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine | TA440 | | |
Ixekizumab for treating moderate to severe plaque psoriasis | TA442 | | |
Obeticholic acid for treating primary biliary cholangitis | TA443 | | |
Antisocial behaviour and conduct disorders in children and young people: recognition and management | CG158 | | |
Alcohol-use disorders: diagnosis and management of physical complications | CG100 | | |
Sexually transmitted infections: condom distribution schemes | NG68 | | |
Minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain | IPG578 | | |
Irritable bowel syndrome in adults: diagnosis and management | CG61 | | |
Managing medicines for adults receiving social care in the community | NG67 | | |
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) | TA240 | | |
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | TA438 | | |
Patient group directions | MPG2 | | |
Extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women | IPG576 | | |
Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse | IPG577 | | |
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) | TA436 | | |
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) | TA437 | | |
Elotuzumab for previously treated multiple myeloma (terminated appraisal) | TA434 | | |
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) | TA435 | | |
Mental health of adults in contact with the criminal justice system | NG66 | | |
Ustekinumab for treating active psoriatic arthritis | TA340 | | |
Ustekinumab for the treatment of adults with moderate to severe psoriasis | TA180 | | |
Migalastat for treating Fabry disease | HST4 | | |
Lateral interbody fusion in the lumbar spine for low back pain | IPG574 | | |
Trabecular stent bypass microsurgery for open-angle glaucoma | IPG575 | | |
Drug misuse prevention: targeted interventions | NG64 | | |
Everolimus for advanced renal cell carcinoma after previous treatment | TA432 | | |
Apremilast for treating active psoriatic arthritis | TA433 | | |
Healthcare-associated infections: prevention and control in primary and community care | CG139 | | |
HumiGard for preventing inadvertent perioperative hypothermia | MTG31 | | |
Osteoporosis: assessing the risk of fragility fracture | CG146 | | |
Cerebral palsy in under 25s: assessment and management | NG62 | | |
Antimicrobial stewardship: changing risk-related behaviours in the general population | NG63 | | |
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | TA429 | | |
Sofosbuvir–velpatasvir for treating chronic hepatitis C | TA430 | | |
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib | TA427 | | |
Organ donation for transplantation: improving donor identification and consent rates for deceased organ donation | CG135 | | |
Extracorporeal shockwave therapy for Achilles tendinopathy | IPG571 | | |
Radiation therapy for early Dupuytren's disease | IPG573 | | |
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy | TA421 | | |
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA422 | | |
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens | TA423 | | |
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | TA424 | | |
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | TA425 | | |
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia | TA426 | | |
Hypothermia: prevention and management in adults having surgery | CG65 | | |
Epiduroscopic lumbar discectomy through the sacral hiatus for sciatica | IPG570 | | |
Ticagrelor for preventing atherothrombotic events after myocardial infarction | TA420 | | |
XprESS multi sinus dilation system for treating chronic sinusitis | MTG30 | | |
HIV testing: increasing uptake among people who may have undiagnosed HIV | NG60 | | |
Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis | CG95 | | |
Coexisting severe mental illness and substance misuse: community health and social care services | NG58 | | |
Spasticity in under 19s: management | CG145 | | |
Endoscopic transluminal pancreatic necrosectomy | IPG567 | | |
Percutaneous insertion of craniocaudal expandable implants for vertebral compression fracture | IPG568 | | |
Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity | IPG569 | | |
Dapagliflozin in combination therapy for treating type 2 diabetes | TA288 | | |
Nivolumab for previously treated advanced renal cell carcinoma | TA417 | | |
Dapagliflozin in triple therapy for treating type 2 diabetes | TA418 | | |
Apremilast for treating moderate to severe plaque psoriasis | TA419 | | |
Physical health of people in prison | NG57 | | |
Psychosis and schizophrenia in children and young people: recognition and management | CG155 | | |
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor | TA415 | | |
Elbasvir–grazoprevir for treating chronic hepatitis C | TA413 | | |
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma | TA414 | | |
Single-incision short sling mesh insertion for stress urinary incontinence in women | IPG566 | | |
Miniature lens system implantation for advanced age-related macular degeneration | IPG565 | | |
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer | TA411 | | |
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | TA412 | | |
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA406 | | |
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors | TA407 | | |
Pegaspargase for treating acute lymphoblastic leukaemia | TA408 | | |
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | | |
Talimogene laherparepvec for treating unresectable metastatic melanoma | TA410 | | |
Multimorbidity: clinical assessment and management | NG56 | | |
Harmful sexual behaviour among children and young people | NG55 | | |
Mental health problems in people with learning disabilities: prevention, assessment and management | NG54 | | |
Transition between inpatient mental health settings and community or care home settings | NG53 | | |
Stable angina: management | CG126 | | |
Acute upper gastrointestinal bleeding in over 16s: management | CG141 | | |
Bosutinib for previously treated chronic myeloid leukaemia | TA401 | | |
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin | TA402 | | |
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer | TA403 | | |
Degarelix for treating advanced hormone-dependent prostate cancer | TA404 | | |
Trifluridine–tipiracil for previously treated metastatic colorectal cancer | TA405 | | |
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel | TA391 | | |
Palliative care for adults: strong opioids for pain relief | CG140 | | |
Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation | IPG563 | | |
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen | TA259 | | |
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation | TA398 | | |
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts | TA399 | | |
Nivolumab in combination with ipilimumab for treating advanced melanoma | TA400 | | |
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA387 | | |
Non-Hodgkin's lymphoma: diagnosis and management | NG52 | | |
Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures | CG64 | | |
Non-alcoholic fatty liver disease (NAFLD): assessment and management | NG49 | | |
Oral health for adults in care homes | NG48 | | |
Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects | IPG560 | | |
Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting | IPG561 | | |
Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules | IPG562 | | |
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA393 | | |
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA394 | | |
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer | TA395 | | |
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | TA396 | | |
Adalimumab for treating moderate to severe hidradenitis suppurativa | TA392 | | |
Endovenous mechanochemical ablation for varicose veins | IPG557 | | |
Haematological cancers: improving outcomes | NG47 | | |
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | TA390 | | |
Microwave ablation for treating liver metastases | IPG553 | | |
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension | IPG554 | | |
Percutaneous interlaminar endoscopic lumbar discectomy for sciatica | IPG555 | | |
Percutaneous transforaminal endoscopic lumbar discectomy for sciatica | IPG556 | | |
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction | TA388 | | |
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer | TA389 | | |
Controlled drugs: safe use and management | NG46 | | |
Routine preoperative tests for elective surgery | NG45 | | |
Workplace health: management practices | NG13 | | |
Corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis | IPG551 | | |
Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine | IPG552 | | |
Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia | IPG550 | | |
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis | TA386 | | |
Community engagement: improving health and wellbeing and reducing health inequalities | NG44 | | |
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) | TA23 | | |
Spectra Optia for automatic red blood cell exchange in people with sickle cell disease | MTG28 | | |
Angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction | IPG546 | | |
Mechanical clot retrieval for treating acute ischaemic stroke | IPG548 | | |
Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death | IPG549 | | |
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia | TA385 | | |
Transition from children's to adults' services for young people using health or social care services | NG43 | | |
Nivolumab for treating advanced (unresectable or metastatic) melanoma | TA384 | | |
Fractures (non-complex): assessment and management | NG38 | | |
Major trauma: assessment and initial management | NG39 | | |
Major trauma: service delivery | NG40 | | |
Spinal injury: assessment and initial management | NG41 | | |
Skin cancer prevention | PH32 | | |
Sunlight exposure: risks and benefits | NG34 | | |
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | | |
Percutaneous coblation of the intervertebral disc for low back pain and sciatica | IPG543 | | |
Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica | IPG544 | | |
Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain | IPG545 | | |
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA377 | | |
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy | TA378 | | |
Nintedanib for treating idiopathic pulmonary fibrosis | TA379 | | |
Panobinostat for treating multiple myeloma after at least 2 previous treatments | TA380 | | |
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) | TA382 | | |
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | | |
Guidance on the use of imatinib for chronic myeloid leukaemia | TA70 | | |
Older people: independence and mental wellbeing | NG32 | | |
Repetitive transcranial magnetic stimulation for depression | IPG542 | | |
Joint distraction for ankle osteoarthritis | IPG538 | | |
Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma | IPG539 | | |
Electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease | IPG540 | | |
Insertion of a subretinal prosthesis system for retinitis pigmentosa | IPG537 | | |
Care of dying adults in the last days of life | NG31 | | |
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears | TA369 | | |
Bortezomib for previously untreated mantle cell lymphoma | TA370 | | |
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis | TA373 | | |
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy | TA374 | | |
Oral health promotion: general dental practice | NG30 | | |
Transition between inpatient hospital settings and community or care home settings for adults with social care needs | NG27 | | |
Implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyes | IPG534 | | |
Living-donor liver transplantation | IPG535 | | |
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention | IPG536 | | |
Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care | NG26 | | |
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C | TA365 | | |
Vortioxetine for treating major depressive episodes | TA367 | | |
Ledipasvir–sofosbuvir for treating chronic hepatitis C | TA363 | | |
Blood transfusion | NG24 | | |
Older people with social care needs and multiple long-term conditions | NG22 | | |
Implanting a baroreceptor stimulation device for resistant hypertension | IPG533 | | |
Developing and updating local formularies | MPG1 | | |
Tolvaptan for treating autosomal dominant polycystic kidney disease | TA358 | | |
Idelalisib for treating chronic lymphocytic leukaemia | TA359 | | |
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) | TA362 | | |
Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset | NG16 | | |
Low energy contact X-ray brachytherapy (the Papillon technique) for early stage rectal cancer | IPG532 | | |
Home care: delivering personal care and practical support to older people living in their own homes | NG21 | | |
Coeliac disease: recognition, assessment and management | NG20 | | |
Preoperative high dose rate brachytherapy for rectal cancer | IPG531 | | |
Transcranial direct current stimulation (tDCS) for depression | IPG530 | | |
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy | TA352 | | |
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) | TA353 | | |
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism | TA354 | | |
Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use | NG15 | | |
Insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section | IPG528 | | |
Joint distraction for knee osteoarthritis without alignment correction | IPG529 | | |
Naloxegol for treating opioid‑induced constipation | TA345 | | |
Aflibercept for treating diabetic macular oedema | TA346 | | |
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer | TA347 | | |
Everolimus for preventing organ rejection in liver transplantation | TA348 | | |
Secukinumab for treating moderate to severe plaque psoriasis | TA350 | | |
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) | TA351 | | |
Suture fixation of acute disruption of the distal tibiofibular syndesmosis | IPG521 | | |
Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis | IPG523 | | |
Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism | IPG524 | | |
Electrotherapy for the treatment of haemorrhoids | IPG525 | | |
Implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache | IPG527 | | |
Insertion of an epiretinal prosthesis for retinitis pigmentosa | IPG519 | | |
Radiofrequency ablation for gastric antral vascular ectasia | IPG520 | | |
Omalizumab for previously treated chronic spontaneous urticaria | TA339 | | |
Vedolizumab for treating moderately to severely active ulcerative colitis | TA342 | | |
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA341 | | |
Lower urinary tract symptoms in men: management | CG97 | | |
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia | TA343 | | |
Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges | NG11 | | |
Violence and aggression: short-term management in mental health, health and community settings | NG10 | | |
Insertion of a balloon device to disimpact an engaged fetal head before an emergency caesarean section | IPG515 | | |
Implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation | IPG516 | | |
Insertion of endobronchial nitinol coils to improve lung function in emphysema | IPG517 | | |
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes | IPG518 | | |
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome | TA335 | | |
Empagliflozin in combination therapy for treating type 2 diabetes | TA336 | | |
Rifaximin for preventing episodes of overt hepatic encephalopathy | TA337 | | |
Obesity prevention | CG43 | | |
Preventing excess weight gain | NG7 | | |
Excess winter deaths and illness and the health risks associated with cold homes | NG6 | | |
Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes | NG5 | | |
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy | MTG22 | | |
Safe midwifery staffing for maternity settings | NG4 | | |
Bladder cancer: diagnosis and management | NG2 | | |
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | | |
Sofosbuvir for treating chronic hepatitis C | TA330 | | |
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment | TA333 | | |
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) | TA334 | | |
Flexible endoscopic treatment of a pharyngeal pouch | IPG513 | | |
Eculizumab for treating atypical haemolytic uraemic syndrome | HST1 | | |
Implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis | IPG512 | | |
Open reduction of slipped capital femoral epiphysis | IPG511 | | |
Hysteroscopic metroplasty of a uterine septum for primary infertility | IPG509 | | |
Hysteroscopic metroplasty of a uterine septum for recurrent miscarriage | IPG510 | | |
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma | TA269 | | |
Single‑incision laparoscopic cholecystectomy | IPG508 | | |
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA327 | | |
Telemetric adjustable pulmonary artery banding for pulmonary hypertension in infants with congenital heart defects | IPG505 | | |
Insertion of an annular disc implant at lumbar discectomy | IPG506 | | |
Insertion of a collagen plug to close an abdominal wall enterocutaneous fistula | IPG507 | | |
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy | TA323 | | |
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block | TA324 | | |
Nalmefene for reducing alcohol consumption in people with alcohol dependence | TA325 | | |
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours | TA326 | | |
The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury | MTG21 | | |
Maternal and child nutrition | PH11 | | |
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block | TA88 | | |
Gallstone disease: diagnosis and management | CG188 | | |
Oral health: local authorities and partners | PH55 | | |
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma | TA321 | | |
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence | CG115 | | |
Combined endoscopic and laparoscopic removal of colonic polyps | IPG503 | | |
Physical activity: exercise referral schemes | PH54 | | |
Drug allergy: diagnosis and management | CG183 | | |
Total prosthetic replacement of the temporomandibular joint | IPG500 | | |
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis | TA320 | | |
Minimally invasive video-assisted thyroidectomy | IPG499 | | |
Minimally invasive video‑assisted parathyroidectomy | IPG501 | | |
Assessing motility of the gastrointestinal tract using a wireless capsule | IPG502 | | |
Endoscopic radiofrequency ablation for Barrett's oesophagus with low‑grade dysplasia or no dysplasia | IPG496 | | |
Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus | IPG497 | | |
Powered microdebrider turbinoplasty for inferior turbinate hypertrophy | IPG498 | | |
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen | TA316 | | |
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes | TA317 | | |
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma | TA319 | | |
Safe staffing for nursing in adult inpatient wards in acute hospitals | SG1 | | |
Endoscopic saphenous vein harvest for coronary artery bypass grafting | IPG494 | | |
Radiofrequency tissue reduction for turbinate hypertrophy | IPG495 | | |
The geko device for reducing the risk of venous thromboembolism | MTG19 | | |
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure | TA314 | | |
Canagliflozin in combination therapy for treating type 2 diabetes | TA315 | | |
Teriflunomide for treating relapsing–remitting multiple sclerosis | TA303 | | |
Gastroelectrical stimulation for gastroparesis | IPG489 | | |
Weight management: lifestyle services for overweight or obese adults | PH53 | | |
Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb | IPG487 | | |
Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee | IPG493 | | |
Pressure ulcers: prevention and management | CG179 | | |
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | | |
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation | TA311 | | |
Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults | IPG482 | | |
Insertion of a magnetic bead band for faecal incontinence | IPG483 | | |
Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy | IPG484 | | |
Faecal microbiota transplant for recurrent Clostridium difficile infection | IPG485 | | |
Contraceptive services for under 25s | PH51 | | |
Needle and syringe programmes | PH52 | | |
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis | TA308 | | |
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy | TA307 | | |
Managing medicines in care homes | SC1 | | |
Psychosis and schizophrenia in adults: prevention and management | CG178 | | |
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma | IPG478 | | |
Domestic violence and abuse: multi-agency working | PH50 | | |
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip | TA304 | | |
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | | |
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma | TA306 | | |
Optical coherence tomography to guide percutaneous coronary intervention | IPG481 | | |
Endoscopic thoracic sympathectomy for primary facial blushing | IPG480 | | |
Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia | IPG475 | | |
Transcranial magnetic stimulation for treating and preventing migraine | IPG477 | | |
Arthroscopic trochleoplasty for patellar instability | IPG474 | | |
Radiofrequency ablation of the soft palate for snoring | IPG476 | | |
Behaviour change: individual approaches | PH49 | | |
Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events | IPG472 | | |
Uterine artery embolisation for treating adenomyosis | IPG473 | | |
Negative pressure wound therapy for the open abdomen | IPG467 | | |
Phrenic nerve transfer in brachial plexus injury | IPG468 | | |
Implantation of a duodenal–jejunal bypass sleeve for managing obesity | IPG471 | | |
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people | TA300 | | |
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) | TA302 | | |
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C | TA106 | | |
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C | TA75 | | |
Weight management: lifestyle services for overweight or obese children and young people | PH47 | | |
Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia | IPG466 | | |
Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease | IPG461 | | |
Translaryngeal tracheostomy | IPG462 | | |
Pazopanib for the first-line treatment of advanced renal cell carcinoma | TA215 | | |
Varicose veins: diagnosis and management | CG168 | | |
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder | TA292 | | |
Aflibercept solution for injection for treating wet age‑related macular degeneration | TA294 | | |
Insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction | IPG457 | | |
Selective internal radiation therapy for primary hepatocellular carcinoma | IPG460 | | |
Insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction | IPG449 | | |
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | TA287 | | |
Mirabegron for treating symptoms of overactive bladder | TA290 | | |
Falls in older people: assessing risk and prevention | CG161 | | |
Physical activity: brief advice for adults in primary care | PH44 | | |
Social anxiety disorder: recognition, assessment and treatment | CG159 | | |
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | TA284 | | |
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer | TA285 | | |
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) | TA286 | | |
Occipital nerve stimulation for intractable chronic migraine | IPG452 | | |
Corneal inlay implantation for correction of presbyopia | IPG455 | | |
Omalizumab for treating severe persistent allergic asthma | TA278 | | |
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures | TA279 | | |
Antisocial personality disorder: prevention and management | CG77 | | |
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma | IPG446 | | |
Insertion of endobronchial valves for persistent air leaks | IPG448 | | |
Percutaneous electrical nerve stimulation for refractory neuropathic pain | IPG450 | | |
Peripheral nerve-field stimulation for chronic low back pain | IPG451 | | |
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis | TA276 | | |
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) | TA277 | | |
Hepatitis B and C testing: people at risk of infection | PH43 | | |
Irreversible electroporation for treating primary lung cancer and metastases in the lung | IPG441 | | |
Irreversible electroporation for treating renal cancer | IPG443 | | |
Irreversible electroporation for treating liver metastases | IPG445 | | |
Ultrasound-guided foam sclerotherapy for varicose veins | IPG440 | | |
Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction | IPG436 | | |
Autologous blood injection for plantar fasciitis | IPG437 | | |
Autologous blood injection for tendinopathy | IPG438 | | |
Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy | IPG439 | | |
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract | TA272 | | |
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | TA273 | | |
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma | TA268 | | |
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) | TA270 | | |
Dronedarone for the treatment of non-permanent atrial fibrillation | TA197 | | |
Physical activity: walking and cycling | PH41 | | |
Mannitol dry powder for inhalation for treating cystic fibrosis | TA266 | | |
Ivabradine for treating chronic heart failure | TA267 | | |
Laparoscopic gastric plication for the treatment of severe obesity | IPG432 | | |
Percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease | IPG433 | | |
Radiofrequency cold ablation for respiratory papillomatosis | IPG434 | | |
Social and emotional wellbeing: early years | PH40 | | |
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours | TA265 | | |
Alteplase for treating acute ischaemic stroke | TA264 | | |
Neutropenic sepsis: prevention and management in people with cancer | CG151 | | |
Mega Soft Patient Return Electrode for use during monopolar electrosurgery | MTG11 | | |
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer | TA263 | | |
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | TA261 | | |
Endovascular stent insertion for intracranial atherosclerotic disease | IPG429 | | |
Partial replacement of the meniscus of the knee using a biodegradable scaffold | IPG430 | | |
Sickle cell disease: managing acute painful episodes in hospital | CG143 | | |
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 | TA257 | | |
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer | TA258 | | |
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | TA260 | | |
Percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation | IPG427 | | |
Focal therapy using cryoablation for localised prostate cancer | IPG423 | | |
Micropressure therapy for refractory Ménière's disease | IPG426 | | |
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis | TA254 | | |
Incisionless otoplasty | IPG422 | | |
Pharmalgen for the treatment of bee and wasp venom allergy | TA246 | | |
Tocilizumab for the treatment of rheumatoid arthritis | TA247 | | |
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy | TA242 | | |
Rituximab for the first-line treatment of stage III-IV follicular lymphoma | TA243 | | |
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults | TA245 | | |
Breast reconstruction using lipomodelling after breast cancer treatment | IPG417 | | |
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer | TA118 | | |
Epiretinal brachytherapy for wet age-related macular degeneration | IPG415 | | |
Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services | CG136 | | |
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis | TA238 | | |
Fulvestrant for the treatment of locally advanced or metastatic breast cancer | TA239 | | |
Drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants | IPG412 | | |
Magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids | IPG413 | | |
Single-port laparoscopic nephrectomy | IPG414 | | |
Healthcare-associated infections: prevention and control | PH36 | | |
Ticagrelor for the treatment of acute coronary syndromes | TA236 | | |
Mifamurtide for the treatment of osteosarcoma | TA235 | | |
Arthroscopic femoro–acetabular surgery for hip impingement syndrome | IPG408 | | |
Minimally invasive oesophagectomy | IPG407 | | |
Laparoscopic cryotherapy for renal cancer | IPG405 | | |
Percutaneous cryotherapy for renal cancer | IPG402 | | |
Open femoro–acetabular surgery for hip impingement syndrome | IPG403 | | |
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma | TA228 | | |
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion | TA229 | | |
Agomelatine for the treatment of major depressive episodes (terminated appraisal) | TA231 | | |
Ambulight PDT for the treatment of non-melanoma skin cancer | MTG6 | | |
The MIST Therapy system for the promotion of wound healing | MTG5 | | |
Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction | TA73 | | |
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer | TA227 | | |
Endoscopic radical inguinal lymphadenectomy | IPG398 | | |
Thoracoscopic exclusion of the left atrial appendage (with or without surgical ablation) for non-valvular atrial fibrillation for the prevention of thromboembolism | IPG400 | | |
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs | TA225 | | |
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma | TA226 | | |
Endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence | IPG393 | | |
Percutaneous tibial nerve stimulation for faecal incontinence | IPG395 | | |
Trabeculotomy ab interno for open angle glaucoma | IPG397 | | |
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease | TA223 | | |
Type 2 diabetes prevention: population and community-level interventions | PH35 | | |
Carotid artery stent placement for symptomatic extracranial carotid stenosis | IPG389 | | |
Endovascular stent-grafting of popliteal aneurysms | IPG390 | | |
Extracorporeal membrane oxygenation for severe acute respiratory failure in adults | IPG391 | | |
Stent insertion for bleeding oesophageal varices | IPG392 | | |
Golimumab for the treatment of psoriatic arthritis | TA220 | | |
Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings | CG120 | | |
Hand allotransplantation | IPG383 | | |
Percutaneous retroperitoneal endoscopic necrosectomy | IPG384 | | |
Laser correction of refractive error following non-refractive ophthalmic surgery | IPG385 | | |
Deep brain stimulation for intractable trigeminal autonomic cephalalgias | IPG381 | | |
Deep brain stimulation for refractory chronic pain syndromes (excluding headache) | IPG382 | | |
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia | TA218 | | |
Food allergy in under 19s: assessment and diagnosis | CG116 | | |
Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices | IPG380 | | |
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer | TA214 | | |
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia | TA216 | | |
Extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome | IPG376 | | |
Off-pump coronary artery bypass grafting | IPG377 | | |
Percutaneous laser coronary angioplasty | IPG378 | | |
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | TA213 | | |
Thoracoscopic repair of congenital diaphragmatic hernia in neonates | IPG379 | | |
Distal iliotibial band lengthening for refractory greater trochanteric pain syndrome | IPG375 | | |
Sedation in under 19s: using sedation for diagnostic and therapeutic procedures | CG112 | | |
Cryotherapy for the treatment of liver metastases | IPG369 | | |
Percutaneous closure of patent foramen ovale for recurrent migraine | IPG370 | | |
Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers | IPG371 | | |
Percutaneous radiofrequency ablation for primary or secondary lung cancers | IPG372 | | |
Selective dorsal rhizotomy for spasticity in cerebral palsy | IPG373 | | |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events | TA210 | | |
Prucalopride for the treatment of chronic constipation in women | TA211 | | |
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer | TA212 | | |
Interspinous distraction procedures for lumbar spinal stenosis causing neurogenic claudication | IPG365 | | |
Non-rigid stabilisation techniques for the treatment of low back pain | IPG366 | | |
Uterine artery embolisation for fibroids | IPG367 | | |
Unintentional injuries: prevention strategies for under 15s | PH29 | | |
Unintentional injuries in the home: interventions for under 15s | PH30 | | |
Unintentional injuries on the road: interventions for under 15s | PH31 | | |
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer | TA208 | | |
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours | TA209 | | |
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours | TA86 | | |
Bedwetting in under 19s | CG111 | | |
Endoscopic mucosal resection and endoscopic submucosal dissection of non-ampullary duodenal lesions | IPG359 | | |
Endoscopic submucosal dissection of gastric lesions | IPG360 | | |
Insertion of metal rib reinforcements to stabilise a flail chest wall | IPG361 | | |
Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome | IPG362 | | |
Minimally invasive total hip replacement | IPG363 | | |
Transperineal template biopsy and mapping of the prostate | IPG364 | | |
Denosumab for the prevention of osteoporotic fractures in postmenopausal women | TA204 | | |
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) | TA206 | | |
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA207 | | |
Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factors | CG110 | | |
Endoscopic submucosal dissection of oesophageal dysplasia and neoplasia | IPG355 | | |
Laparoscopic hysterectomy (including laparoscopic total hysterectomy and laparoscopically assisted vaginal hysterectomy) for endometrial cancer | IPG356 | | |
Percutaneous intradiscal laser ablation in the lumbar spine | IPG357 | | |
Phototherapeutic laser keratectomy for corneal surface irregularities | IPG358 | | |
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C | TA200 | | |
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | TA195 | | |
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | TA199 | | |
Percutaneous mitral valve annuloplasty | IPG352 | | |
Percutaneous radiofrequency ablation for renal cancer | IPG353 | | |
Shoulder resurfacing arthroplasty | IPG354 | | |
Weight management before, during and after pregnancy | PH27 | | |
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia | TA193 | | |
Capecitabine for the treatment of advanced gastric cancer | TA191 | | |
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer | TA192 | | |
Stapled transanal rectal resection for obstructed defaecation syndrome | IPG351 | | |
Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism | IPG349 | | |
Photodynamic therapy for Barrett's oesophagus | IPG350 | | |
Cardiovascular disease prevention | PH25 | | |
Alcohol-use disorders: prevention | PH24 | | |
Epithelial radiofrequency ablation for Barrett's oesophagus | IPG344 | | |
Mini-incision surgery for total knee replacement | IPG345 | | |
Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury | IPG347 | | |
Human growth hormone (somatropin) for the treatment of growth failure in children | TA188 | | |
Improving outcomes for people with skin tumours including melanoma | CSG8 | | |
Limited macular translocation for wet age-related macular degeneration | IPG339 | | |
Macular translocation with 360° retinotomy for wet age-related macular degeneration | IPG340 | | |
Prosthetic intervertebral disc replacement in the cervical spine | IPG341 | | |
Haemorrhoidal artery ligation | IPG342 | | |
Infliximab and adalimumab for the treatment of Crohn's disease | TA187 | | |
Arteriovenous crossing sheathotomy for branch retinal vein occlusion | IPG334 | | |
Endoscopic submucosal dissection of lower gastrointestinal lesions | IPG335 | | |
Transcatheter endovascular closure of perimembranous ventricular septal defect | IPG336 | | |
Endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions | IPG337 | | |
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes | TA47 | | |
Donor milk banks: service operation | CG93 | | |
Surgical correction of hallux valgus using minimal access techniques | IPG332 | | |
Therapeutic endoscopic division of epidural adhesions | IPG333 | | |
Radiofrequency ablation for colorectal liver metastases | IPG327 | | |
Suction diathermy adenoidectomy | IPG328 | | |
Balloon catheter insertion for Bartholin's cyst or abscess | IPG323 | | |
Electrocautery cutting balloon treatment for pelviureteric junction obstruction | IPG324 | | |
Endopyelotomy for pelviureteric junction obstruction | IPG325 | | |
Laparoscopic augmentation cystoplasty (including clam cystoplasty) | IPG326 | | |
Topotecan for the treatment of relapsed small-cell lung cancer | TA184 | | |
Depression in adults with a chronic physical health problem: recognition and management | CG91 | | |
Topotecan for the treatment of recurrent and stage IVB cervical cancer | TA183 | | |
Guidance on the use of electroconvulsive therapy | TA59 | | |
Extracorporeal albumin dialysis for acute liver failure | IPG316 | | |
Individually magnetic resonance imaging-designed unicompartmental interpositional implant insertion for osteoarthritis of the knee | IPG317 | | |
Sunitinib for the treatment of gastrointestinal stromal tumours | TA179 | | |
Pemetrexed for the first-line treatment of non-small-cell lung cancer | TA181 | | |
Placement of pectus bar for pectus excavatum (also known as MIRPE or the Nuss procedure) | IPG310 | | |
Extracorporeal shockwave therapy for refractory plantar fasciitis | IPG311 | | |
Extracorporeal shockwave therapy for refractory tennis elbow | IPG313 | | |
Alitretinoin for the treatment of severe chronic hand eczema | TA177 | | |
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma | TA178 | | |
Prosthetic intervertebral disc replacement in the lumbar spine | IPG306 | | |
Image-guided radiofrequency excision biopsy of breast lesions | IPG308 | | |
Sinus tarsi implant insertion for mobile flatfoot | IPG305 | | |
Tenofovir disoproxil for the treatment of chronic hepatitis B | TA173 | | |
Rituximab for the first-line treatment of chronic lymphocytic leukaemia | TA174 | | |
Percutaneous endoscopic laser cervical discectomy | IPG303 | | |
Corneal endothelial transplantation | IPG304 | | |
Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions) | IPG299 | | |
Transmyocardial laser revascularisation for refractory angina pectoris | IPG301 | | |
Percutaneous laser revascularisation for refractory angina pectoris | IPG302 | | |
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management | CG84 | | |
Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD) | IPG297 | | |
Ex-vivo hepatic resection and reimplantation for liver cancer | IPG298 | | |
Endoscopic mastectomy and endoscopic wide local excision for breast cancer | IPG296 | | |
Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults | TA170 | | |
Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation | IPG294 | | |
Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia | IPG295 | | |
Rehabilitation after critical illness in adults | CG83 | | |
Photodynamic therapy for brain tumours | IPG290 | | |
Implantation of an opaque intraocular lens for intractable double vision | IPG293 | | |
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma | TA169 | | |
Extracorporeal photopheresis for Crohn's disease | IPG288 | | |
Intraocular lens insertion for correction of refractive error, with preservation of the natural lens | IPG289 | | |
Laparoscopic cystectomy | IPG287 | | |
Amantadine, oseltamivir and zanamivir for the treatment of influenza | TA168 | | |
Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence | CG76 | | |
Borderline personality disorder: recognition and management | CG78 | | |
Functional electrical stimulation for drop foot of central neurological origin | IPG278 | | |
Ultrasound-guided regional nerve block | IPG285 | | |
Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation | IPG286 | | |
Physical activity for children and young people | PH17 | | |
Machine perfusion systems and cold static storage of kidneys from deceased donors | TA165 | | |
Infliximab for acute exacerbations of ulcerative colitis | TA163 | | |
Laparoscopic prostatectomy for benign prostatic obstruction | IPG275 | | |
Transabdominal artificial bowel sphincter implantation for faecal incontinence | IPG276 | | |
Mental wellbeing in over 65s: occupational therapy and physical activity interventions | PH16 | | |
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin | TA159 | | |
Balloon catheter dilation of paranasal sinus ostia for chronic sinusitis | IPG273 | | |
Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy | IPG274 | | |
Cardiovascular disease: identifying and supporting people most at risk of dying early | PH15 | | |
Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults | TA157 | | |
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza | TA158 | | |
Total wrist replacement | IPG271 | | |
Routine antenatal anti-D prophylaxis for women who are rhesus D negative | TA156 | | |
Entecavir for the treatment of chronic hepatitis B | TA153 | | |
Telbivudine for the treatment of chronic hepatitis B | TA154 | | |
Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision | IPG268 | | |
Laparoscopic gastrectomy for cancer | IPG269 | | |
Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants | IPG270 | | |
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus | TA151 | | |
Lumbar infusion test for the investigation of normal pressure hydrocephalus | IPG263 | | |
Implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery | IPG264 | | |
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) | TA148 | | |
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) | TA149 | | |
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck | TA145 | | |
Adalimumab for the treatment of adults with psoriasis | TA146 | | |
Endoaortic balloon occlusion for cardiac surgery | IPG261 | | |
Physical activity in the workplace | PH13 | | |
Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy | IPG258 | | |
Interstitial photodynamic therapy for malignant parotid tumours | IPG259 | | |
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus | IPG257 | | |
Intraoperative nerve monitoring during thyroid surgery | IPG255 | | |
Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over | TA138 | | |
Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion | IPG252 | | |
Laparoscopic mobilisation of the greater omentum for breast reconstruction | IPG253 | | |
Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses | IPG254 | | |
Structural neuroimaging in first-episode psychosis | TA136 | | |
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma | TA137 | | |
Ultrasound-guided catheterisation of the epidural space | IPG249 | | |
Infliximab for the treatment of adults with psoriasis | TA134 | | |
Pemetrexed for the treatment of malignant pleural mesothelioma | TA135 | | |
Thoracoscopically assisted mitral valve surgery | IPG245 | | |
Hybrid procedure for interim management of hypoplastic left heart syndrome in neonates | IPG246 | | |
Thoracoscopic excision of mediastinal parathyroid tumours | IPG247 | | |
Thoracoscopic aortopexy for severe primary tracheomalacia | IPG243 | | |
Grenz rays therapy for inflammatory skin conditions | IPG236 | | |
Mini/micro screw implantation for orthodontic anchorage | IPG238 | | |
Laparoscopic techniques for hysterectomy | IPG239 | | |
Soft-palate implants for simple snoring | IPG240 | | |
Soft-palate implants for obstructive sleep apnoea | IPG241 | | |
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years | TA131 | | |
Laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain | IPG234 | | |
Behaviour change: general approaches | PH6 | | |
Bortezomib monotherapy for relapsed multiple myeloma | TA129 | | |
Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children | IPG232 | | |
Stapled haemorrhoidopexy for the treatment of haemorrhoids | TA128 | | |
Laparoscopic repair of abdominal aortic aneurysm | IPG229 | | |
Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis | IPG230 | | |
Pemetrexed for the treatment of non-small-cell lung cancer | TA124 | | |
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis | TA127 | | |
Therapeutic percutaneous image-guided aspiration of spinal cysts | IPG223 | | |
Acutely ill adults in hospital: recognising and responding to deterioration | CG50 | | |
Drug misuse in over 16s: opioid detoxification | CG52 | | |
Drug misuse in over 16s: psychosocial interventions | CG51 | | |
Laparoscopic deroofing of simple renal cysts | IPG226 | | |
Corneal implants for keratoconus | IPG227 | | |
Corneal implants for the correction of refractive error | IPG225 | | |
Varenicline for smoking cessation | TA123 | | |
Faecal incontinence in adults: management | CG49 | | |
Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease | IPG222 | | |
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma | TA121 | | |
Therapeutic sialendoscopy | IPG218 | | |
Lower limb deep vein valve reconstruction for chronic deep venous incompetence | IPG219 | | |
Tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium | IPG216 | | |
Laparoscopic nephrolithotomy and pyelolithotomy | IPG212 | | |
Microwave ablation of hepatocellular carcinoma | IPG214 | | |
Radiofrequency-assisted liver resection | IPG211 | | |
Laparoscopic insertion of peritoneal dialysis catheter | IPG208 | | |
Implantation of accommodating intraocular lenses for cataract | IPG209 | | |
Injectable bulking agents for faecal incontinence | IPG210 | | |
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia | TA119 | | |
Laparoscopic distal pancreatectomy | IPG204 | | |
Fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction | IPG205 | | |
Palliative photodynamic therapy for advanced oesophageal cancer | IPG206 | | |
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy | TA117 | | |
Methadone and buprenorphine for the management of opioid dependence | TA114 | | |
Naltrexone for the management of opioid dependence | TA115 | | |
Gemcitabine for the treatment of metastatic breast cancer | TA116 | | |
Intrauterine laser ablation of placental vessels for the treatment of twin-to-twin transfusion syndrome | IPG198 | | |
Septostomy with or without amnioreduction for the treatment of twin-to-twin transfusion syndrome | IPG199 | | |
Photodynamic therapy for early-stage oesophageal cancer | IPG200 | | |
Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction | IPG202 | | |
Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) | IPG192 | | |
Laparoscopic radical prostatectomy | IPG193 | | |
Insertion of pleuro–amniotic shunt for fetal pleural effusion | IPG190 | | |
Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) | IPG188 | | |
Laparoscopic surgery for colorectal cancer | TA105 | | |
High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery | IPG184 | | |
Tonsillectomy using laser | IPG186 | | |
Catheterless oesophageal pH monitoring | IPG187 | | |
Etanercept and efalizumab for the treatment of adults with psoriasis | TA103 | | |
Improving outcomes for people with brain and other central nervous system tumours | CSG10 | | |
Percutaneous cementoplasty for palliative treatment of bony malignancies | IPG179 | | |
Percutaneous laser therapy for fetal tumours | IPG180 | | |
Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery | IPG177 | | |
Tonsillectomy using ultrasonic scalpel | IPG178 | | |
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer | TA101 | | |
Living-donor lung transplantation for end-stage lung disease | IPG170 | | |
Laparoscopic helium plasma coagulation for the treatment of endometriosis | IPG171 | | |
High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer | IPG174 | | |
Percutaneous fetal balloon valvuloplasty for pulmonary atresia with intact ventricular septum | IPG176 | | |
Percutaneous radiofrequency ablation for atrial fibrillation | IPG168 | | |
Balloon kyphoplasty for vertebral compression fractures | IPG166 | | |
Retrograde urethral sphincterometry | IPG167 | | |
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer | TA100 | | |
Laparoscopic retroperitoneal lymph node dissection for testicular cancer | IPG158 | | |
Stimulated graciloplasty for faecal incontinence | IPG159 | | |
High dose rate brachytherapy for carcinoma of the cervix | IPG160 | | |
Percutaneous endoscopic colostomy | IPG161 | | |
Stent-graft placement in abdominal aortic aneurysm | IPG163 | | |
Photorefractive (laser) surgery for the correction of refractive errors | IPG164 | | |
Endometrial cryotherapy for menorrhagia | IPG157 | | |
Improving outcomes for people with sarcoma | CSG9 | | |
Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) | IPG155 | | |
Image-guided vacuum-assisted excision biopsy of benign breast lesions | IPG156 | | |
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B | TA96 | | |
Laparoscopic partial nephrectomy | IPG151 | | |
Foker technique for long-gap oesophageal atresia | IPG153 | | |
Retrobulbar irradiation for thyroid eye disease | IPG148 | | |
Division of ankyloglossia (tongue-tie) for breastfeeding | IPG149 | | |
Electrosurgery (diathermy and coblation) for tonsillectomy | IPG150 | | |
Direct C1 lateral mass screw for cervical spine stabilisation | IPG146 | | |
Endoscopic axillary lymph node retrieval for breast cancer | IPG147 | | |
Obsessive-compulsive disorder and body dysmorphic disorder: treatment | CG31 | | |
Metatarsophalangeal joint replacement of the hallux | IPG140 | | |
Automated percutaneous mechanical lumbar discectomy | IPG141 | | |
Cryotherapy for malignant endobronchial obstruction | IPG142 | | |
Intraoperative blood cell salvage in obstetrics | IPG144 | | |
Photodynamic therapy for localised inoperable endobronchial cancer | IPG137 | | |
Cryotherapy as a primary treatment for prostate cancer | IPG145 | | |
Intramural urethral bulking procedures for stress urinary incontinence in women | IPG138 | | |
Improving outcomes in children and young people with cancer | CSG7 | | |
Laparoscopic nephrectomy (including nephroureterectomy) | IPG136 | | |
Low dose rate brachytherapy for localised prostate cancer | IPG132 | | |
Photodynamic therapy for bile duct cancer | IPG134 | | |
Laparoscopic liver resection | IPG135 | | |
HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) | TA92 | | |
Leukapheresis for inflammatory bowel disease | IPG126 | | |
Collagen injection for vocal cord augmentation | IPG130 | | |
Endovascular stent–graft placement in thoracic aortic aneurysms and dissections | IPG127 | | |
Interstitial laser therapy for fibroadenomas of the breast | IPG131 | | |
Totally endoscopic robotically assisted coronary artery bypass grafting | IPG128 | | |
Computed tomographic colonography (virtual colonoscopy) | IPG129 | | |
Radiofrequency ablation for atrial fibrillation in association with other cardiac surgery | IPG121 | | |
Microwave ablation for atrial fibrillation in association with other cardiac surgery | IPG122 | | |
Cryoablation for atrial fibrillation in association with other cardiac surgery | IPG123 | | |
Cryotherapy for recurrent prostate cancer | IPG119 | | |
Guidance on the use of paclitaxel in the treatment of ovarian cancer | TA55 | | |
High-intensity focused ultrasound for prostate cancer | IPG118 | | |
Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis | IPG110 | | |
Artificial trapeziometacarpal joint replacement for end-stage osteoarthritis | IPG111 | | |
Endoscopic dacryocystorhinostomy | IPG113 | | |
Lung volume reduction surgery for advanced emphysema | IPG114 | | |
Coil embolisation of ruptured intracranial aneurysms | IPG106 | | |
Auditory brain stem implants | IPG108 | | |
Coil embolisation of unruptured intracranial aneurysms | IPG105 | | |
Wireless capsule endoscopy for investigation of the small bowel | IPG101 | | |
Improving outcomes in head and neck cancers | CSG6 | | |
Sacral nerve stimulation for faecal incontinence | IPG99 | | |
Dental checks: intervals between oral health reviews | CG19 | | |
Radiofrequency valvotomy for pulmonary atresia | IPG95 | | |
Endovascular closure of atrial septal defect | IPG96 | | |
Endovascular closure of patent ductus arteriosus | IPG97 | | |
Intraoperative fluorescence angiography for the evaluation of coronary artery bypass graft patency | IPG98 | | |
Interstitial laser therapy for breast cancer | IPG89 | | |
Intralesional photocoagulation of subcutaneous congenital vascular disorders | IPG90 | | |
Laparoscopic surgery for inguinal hernia repair | TA83 | | |
Selective peripheral denervation for cervical dystonia | IPG80 | | |
Supraorbital minicraniotomy for intracranial aneurysm | IPG84 | | |
Endovascular atrial septostomy | IPG86 | | |
Photodynamic therapy for advanced bronchial carcinoma | IPG87 | | |
Tacrolimus and pimecrolimus for atopic eczema | TA82 | | |
Frequency of application of topical corticosteroids for atopic eczema | TA81 | | |
Balloon dilatation of systemic to pulmonary arterial shunts in children | IPG77 | | |
Balloon valvuloplasty for aortic valve stenosis in adults and children | IPG78 | | |
Balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children | IPG76 | | |
Scleral expansion surgery for presbyopia | IPG70 | | |
Balloon angioplasty of pulmonary vein stenosis in infants | IPG75 | | |
Stent placement for vena caval obstruction | IPG79 | | |
Balloon angioplasty with or without stenting for coarctation or recoarctation of the aorta in adults and children | IPG74 | | |
Fallopian tube recanalisation by guidewire | IPG71 | | |
Insertion of hydrogel keratoprosthesis | IPG69 | | |
Lumbar subcutaneous shunt | IPG68 | | |
Balloon dilatation of pulmonary valve stenosis | IPG67 | | |
Artificial anal sphincter implantation | IPG66 | | |
Subthalamotomy for Parkinson's disease | IPG65 | | |
Sacral nerve stimulation for urge incontinence and urgency-frequency | IPG64 | | |
Falloposcopy with coaxial catheter | IPG62 | | |
Laser sheath removal of pacing leads | IPG63 | | |
Thrombin injections for pseudoaneurysms | IPG60 | | |
Laparoscopic live donor simple nephrectomy | IPG57 | | |
Transpupillary thermotherapy for age-related macular degeneration | IPG58 | | |
Subfascial endoscopic perforator vein surgery | IPG59 | | |
Percutaneous endoscopic laser thoracic discectomy | IPG61 | | |
Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique) | IPG56 | | |
Endoscopic injection of bulking agents for gastro-oesophageal reflux disease | IPG55 | | |
Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia | TA77 | | |
Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding | TA78 | | |
Improving supportive and palliative care for adults with cancer | CSG4 | | |
Photodynamic endometrial ablation | IPG47 | | |
Vagus nerve stimulation for refractory epilepsy in children | IPG50 | | |
Radiotherapy for age-related macular degeneration | IPG49 | | |
Laparoscopic pyeloplasty | IPG46 | | |
Computed tomography-guided thermocoagulation of osteoid osteoma | IPG53 | | |
Endovenous laser treatment of the long saphenous vein | IPG52 | | |
Cyanoacrylate instillation for occlusion of parotid sinuses | IPG42 | | |
Partial left ventriculectomy (the Batista procedure) | IPG41 | | |
Non-surgical reduction of the myocardial septum | IPG40 | | |
Needle fasciotomy for Dupuytren's contracture | IPG43 | | |
Transilluminated powered phlebectomy for varicose veins | IPG37 | | |
Extracorporeal membrane oxygenation (ECMO) in postneonatal children | IPG38 | | |
Pre-hospital initiation of fluid replacement therapy in trauma | TA74 | | |
Circular stapled haemorrhoidectomy | IPG34 | | |
Endoscopic laser foraminoplasty | IPG31 | | |
Laparo-endogastric surgery | IPG25 | | |
Extracorporeal shockwave therapy for Peyronie's disease | IPG29 | | |
Endoscopic transsphenoidal pituitary adenoma resection | IPG32 | | |
Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids | IPG30 | | |
Holmium laser prostatectomy | IPG17 | | |
Bone-anchored cystourethropexy | IPG18 | | |
Deep brain stimulation for Parkinson's disease | IPG19 | | |
Endoscopic stapling of pharyngeal pouch | IPG22 | | |
Laparoscopic laser myomectomy | IPG23 | | |
Transurethral electrovaporisation of the prostate | IPG14 | | |
Guidance on the use of liquid-based cytology for cervical screening | TA69 | | |
Percutaneous vertebroplasty | IPG12 | | |
Radiofrequency ablation of varicose veins | IPG8 | | |
Human growth hormone (somatropin) in adults with growth hormone deficiency | TA64 | | |
Radiofrequency ablation of hepatocellular carcinoma | IPG2 | | |
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer | TA61 | | |
Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction | TA52 | | |
Guidance on the use of ultrasound locating devices for placing central venous catheters | TA49 | | |
Improving outcomes in urological cancers | CSG2 | | |
Improving outcomes in breast cancer | CSG1 | | |
Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) | TA38 | | |
Guidance on the use of trastuzumab for the treatment of advanced breast cancer | TA34 | | |
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia | TA29 | | |
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease | TA20 | | |
Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma | TA10 | | |
Guidance on the extraction of wisdom teeth | TA1 | | |